Literature DB >> 28496733

Risks from Catheter Ablation of Atrial Fibrillation: A Review of Methods, Efficacy, and Safety.

Richard Cheng1, Melisa Chang1, Chee Yuan Ng1.   

Abstract

Atrial fibrillation (AF) is the most common arrhythmia and is a significant burden to healthcare cost. AF causes congestive heart failure, thromboembolic events such as stroke and intolerable symptoms in some patients. With the advances and increasing experience in catheter ablation, there is now an established role for catheter ablation in patients with atrial fibrillation. The risks, complications and patient features associated with it are increasingly recognized. A recent worldwide survey has shown an increasing number of medical centers that are practicing catheter ablation of atrial fibrillation, predominantly with pulmonary vein isolation techniques. However, catheter ablation is an invasive therapy in AF and is associated with a few major complications. Patient selection, ablation technique, and catheter energy source all influence the efficacy and safety of the procedure. Finally, while several randomized control trials have compared the efficacy of catheter ablation versus antiarrhythmic drug therapy, a number of trials are on the horizon to explore its role as a first line therapy for atrial fibrillation. New energy catheter energy sources are also being explored.

Entities:  

Year:  2012        PMID: 28496733      PMCID: PMC5153199          DOI: 10.4022/jafib.455

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  100 in total

1.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy.

Authors:  Christopher C Lang; Vincenzo Santinelli; Giuseppe Augello; Amedeo Ferro; Filippo Gugliotta; Simone Gulletta; Gabriele Vicedomini; Cézar Mesas; Gabriele Paglino; Simone Sala; Nicoleta Sora; Patrizio Mazzone; Francesco Manguso; Carlo Pappone
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

3.  Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Authors:  Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum
Journal:  Value Health       Date:  2006 Sep-Oct       Impact factor: 5.725

4.  Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans.

Authors:  Prashanthan Sanders; Omer Berenfeld; Mélèze Hocini; Pierre Jaïs; Ravi Vaidyanathan; Li-Fern Hsu; Stéphane Garrigue; Yoshihide Takahashi; Martin Rotter; Fréderic Sacher; Christophe Scavée; Robert Ploutz-Snyder; José Jalife; Michel Haïssaguerre
Journal:  Circulation       Date:  2005-08-01       Impact factor: 29.690

5.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.

Authors:  Carlo Pappone; Salvatore Rosanio; Giuseppe Augello; Giuseppe Gallus; Gabriele Vicedomini; Patrizio Mazzone; Simone Gulletta; Filippo Gugliotta; Alessia Pappone; Vincenzo Santinelli; Valter Tortoriello; Simone Sala; Alberto Zangrillo; Giuseppe Crescenzi; Stefano Benussi; Ottavio Alfieri
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

6.  Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation.

Authors:  G Corrado; G Tadeo; S Beretta; L M Tagliagambe; G F Manzillo; M Spata; M Santarone
Journal:  Chest       Date:  1999-01       Impact factor: 9.410

7.  Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy.

Authors:  Giovanni B Forleo; Massimo Mantica; Lucia De Luca; Roberto Leo; Luca Santini; Stefania Panigada; Valerio De Sanctis; Augusto Pappalardo; Francesco Laurenzi; Andrea Avella; Michela Casella; Antonio Dello Russo; Francesco Romeo; Gemma Pelargonio; Claudio Tondo
Journal:  J Cardiovasc Electrophysiol       Date:  2008-09-03

8.  Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function.

Authors:  Michael S Chen; Nassir F Marrouche; Yaariv Khaykin; A Marc Gillinov; Oussama Wazni; David O Martin; Antonio Rossillo; Atul Verma; Jennifer Cummings; Demet Erciyes; Eduardo Saad; Mandeep Bhargava; Dianna Bash; Robert Schweikert; David Burkhardt; Michelle Williams-Andrews; Alejandro Perez-Lugones; Ahmad Abdul-Karim; Walid Saliba; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

9.  Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study.

Authors:  Satoshi Ogawa; Takeshi Yamashita; Tsutomu Yamazaki; Yoshifusa Aizawa; Hirotsugu Atarashi; Hiroshi Inoue; Tohru Ohe; Hiroshi Ohtsu; Ken Okumura; Takao Katoh; Shiro Kamakura; Koichiro Kumagai; Yoshihisa Kurachi; Itsuo Kodama; Yukihiro Koretsune; Tetsunori Saikawa; Masayuki Sakurai; Kaoru Sugi; Toshifumi Tabuchi; Haruaki Nakaya; Toshio Nakayama; Makoto Hirai; Masahiko Fukatani; Hideo Mitamura
Journal:  Circ J       Date:  2008-12-08       Impact factor: 2.993

Review 10.  Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses.

Authors:  Hugh Calkins; Matthew R Reynolds; Peter Spector; Manu Sondhi; Yingxin Xu; Amber Martin; Catherine J Williams; Isabella Sledge
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-06-02
View more
  1 in total

1.  Meta-Analysis of Catheter Ablation versus Medical Therapy for Heart Failure Complicated with Atrial Fibrillation.

Authors:  Xi Zhu; Yingbiao Wu; Zhongping Ning
Journal:  Cardiol Res Pract       Date:  2021-12-06       Impact factor: 1.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.